The Shift From 'Less Bad' to Truly Better
A growing chorus of psychiatrists is pushing back against a quiet but pervasive lowering of the bar in depression care. Writing in Psychiatric Times in April 2026, clinicians treating treatment-resistant depression (TRD) argue that the field has too often accepted partial response — fewer bad days, slightly improved functioning — as a satisfactory outcome. The new framing is more demanding: remission, not just response, should be the target.
For patients who have cycled through multiple antidepressants without meaningful relief, this reorientation matters. TRD is generally defined as failing to respond adequately to at least two antidepressant trials of sufficient dose and duration. It affects an estimated 30% of people diagnosed with major depressive disorder, making it one of the most clinically challenging and consequential conditions in psychiatry.
The article outlines a range of approaches — from augmentation strategies and psychotherapy combinations to newer interventional options — and emphasizes that treatment decisions should be shaped by both clinical evidence and individual patient priorities, including how they weigh side effect burden against speed of response.
Where Ketamine Fits in the TRD Landscape
Ketamine and its derivative esketamine (Spravato) are now well-established within the TRD toolkit, particularly valued for their rapid onset of action — often within hours to days rather than the weeks required by conventional antidepressants. For patients who are acutely suicidal or who have exhausted multiple medication classes, that speed is clinically significant, not just a convenience.
Low-dose ketamine delivered via intravenous infusion, intramuscular injection, or sublingual routes has become increasingly accessible through specialized clinics. The evidence base, while still maturing, supports meaningful antidepressant effects in TRD populations, with remission rates that — while not universal — compare favorably to many other available options at this stage of treatment.
Importantly, the remission-focused framing highlighted in this Psychiatric Times piece aligns with how many ketamine providers think about treatment goals. A short-term infusion series that produces a two-week mood lift is useful; a protocol designed around sustained remission — with appropriate maintenance dosing, psychotherapy integration, and ongoing monitoring — is a different and more ambitious clinical enterprise.
The article's emphasis on balancing side effects with patient priorities is also relevant here. Ketamine carries its own side effect profile: dissociative experiences during administration, potential for misuse in vulnerable populations, cardiovascular considerations, and questions about long-term cognitive effects at therapeutic doses. Informed patients who understand these trade-offs are better positioned to engage meaningfully in treatment decisions.
Key Takeaway
The clinical consensus around treatment-resistant depression is moving toward full remission as the standard of success — not just partial symptom improvement. For patients considering or currently using low-dose ketamine, this means asking your provider not just whether you feel somewhat better, but whether your treatment plan is structured to pursue and sustain remission. Maintenance dosing schedules, adjunctive therapies, and clear outcome measures matter. 'A little better' is not the finish line.
Practical Implications for Ketamine Patients
If you are exploring low-dose ketamine for TRD, this evolving clinical perspective offers several practical takeaways:
- Define remission with your provider. Ask explicitly what symptom scores or functional benchmarks constitute remission for you — not just improvement. Tools like the PHQ-9 or MADRS can give you an objective baseline and help track whether you're reaching genuine remission or settling for partial response.
- Understand maintenance from the start. Initial ketamine infusion series are often six sessions over two to three weeks. But the question of what comes after — monthly boosters, sublingual maintenance, or tapering off with other supports in place — is where the remission goal either holds or collapses. Have this conversation early.
- Weigh the full side effect picture honestly. The remission-first framework doesn't mean pursuing any outcome at any cost. Ketamine's dissociative effects, cost (often out-of-pocket), and monitoring requirements are real factors. A provider who helps you weigh these against your personal priorities is providing better care than one who oversells the treatment.
- Adjunctive therapy is not optional. Most evidence-based TRD protocols that incorporate ketamine also include psychotherapy — particularly modalities like CBT or ketamine-assisted psychotherapy — as a component. Ketamine may open a window of neuroplasticity; what you do in that window affects durability of response.
The broader message from clinicians writing about TRD in 2026 is one of appropriate ambition. Psychiatry has tools now — including ketamine — that were unavailable a decade ago. Using them well means aiming higher than symptom management and building treatment plans that give patients a real shot at sustained, functional recovery.
Read the original clinical discussion at Psychiatric Times.
Share